APA

Folcik V. A., Smith T., O'Bryant S., Kawczak J. A., Zhu B., Sakurai H., Kajiwara A., Staddon J. M., Glabinski A., Chernosky A. L., Tani M., Johnson J. M., Tuohy V. K., Rubin L. L. & Ransohoff R. M. (19990712). Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. : Journal of neuroimmunology.

Chicago

Folcik V A, Smith T, O'Bryant S, Kawczak J A, Zhu B, Sakurai H, Kajiwara A, Staddon J M, Glabinski A, Chernosky A L, Tani M, Johnson J M, Tuohy V K, Rubin L L and Ransohoff R M. 19990712. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. : Journal of neuroimmunology.

Harvard

Folcik V. A., Smith T., O'Bryant S., Kawczak J. A., Zhu B., Sakurai H., Kajiwara A., Staddon J. M., Glabinski A., Chernosky A. L., Tani M., Johnson J. M., Tuohy V. K., Rubin L. L. and Ransohoff R. M. (19990712). Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. : Journal of neuroimmunology.

MLA

Folcik V A, Smith T, O'Bryant S, Kawczak J A, Zhu B, Sakurai H, Kajiwara A, Staddon J M, Glabinski A, Chernosky A L, Tani M, Johnson J M, Tuohy V K, Rubin L L and Ransohoff R M. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. : Journal of neuroimmunology. 19990712.